TORONTO, Dec. 3, 2007 (PRIME NEWSWIRE) -- Polydex Pharmaceuticals Limited (NasdaqCM:POLXF - News) reports that CONRAD, a lead investigator of Ushercell, has commenced a Phase I trial to assess the safety of several vaginal products, including Ushercell, the Company's leading human pharmaceutical candidate compound. The safety study of 60 women is being done using existing and new methodologies for evaluating candidate vaginal products, and includes new safety markers that have not previously been studied in women using any microbicide candidate. In addition to providing information about these products, the study will look at the correlation between clinical and preclinical results, thereby making it easier to use preclinical studies to eliminate products that may have an inflammatory effect.
